查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1411877

子宮內膜癌治療市場：治療方法、等級和最終用戶分類 - 全球預測 2024-2030

Endometrial Cancer Treatment Market by Treatment (Chemotherapy, Immunotherapy, Radiation Therapy), Grade (Type I, Type II), End-User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年子宮內膜癌治療市場規模為84.2億美元，2024年將達88.7億美元，預計2030年將達122.3億美元，複合年成長率為5.47%。

子宮內膜癌治療的全球市場

主要市場統計
基準年[2023] 84.2億美元
預測年份 [2024] 88.7億美元
預測年份 [2030] 122.3億美元
複合年成長率（%） 5.47%
子宮內膜癌治療市場-IMG1

FPNV定位矩陣

FPNV定位矩陣對於評估子宮內膜癌治療市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出資訊的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對子宮內膜癌治療市場供應商的現狀進行深入而詳細的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴考察，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更資訊的決策並制定有效的策略，從而在市場上獲得競爭優勢。

該報告對以下幾個方面提供了寶貴的見解：

1-市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2-市場開拓：我們深入研究利潤豐厚的新興市場並分析其在成熟細分市場的滲透率。

3- 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4-競爭力評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5- 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1-子宮內膜癌治療市場的市場規模與預測是多少？

2-子宮內膜癌治療市場預測期間需要考慮投資的產品、細分市場、應用和領域有哪些？

3-子宮內膜癌治療市場的技術趨勢和法律規範是什麼？

4-子宮內膜癌治療市場主要供應商的市場佔有率是多少？

5-進入子宮內膜癌治療市場合適的型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 1 型和 2 型子宮內膜癌的世界盛行率
      • 政府努力擴大子宮內膜癌治療的採用
      • 個體化和標靶子宮癌治療的出現
    • 抑制因素
      • 子宮內膜治療的報銷結構有限
    • 機會
      • 持續研究開發新的子宮內膜癌治療方法
      • 子宮內膜癌藥物獲得政府有利核准
    • 任務
      • 與特定治療方法相關的監管障礙和風險
  • 市場區隔分析
  • 市場趨勢分析
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範

第6章依治療區分的子宮內膜癌治療市場

  • 化療
  • 免疫療法
  • 放射治療

第7章子宮內膜癌治療市場：依等級

  • Ⅰ型
  • II型

第8章子宮內膜癌治療市場：依最終用戶分類

  • 門診手術中心
  • 癌症中心
  • 醫院和診所

第9章北美及南美子宮內膜癌治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區子宮內膜癌治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲子宮內膜癌治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭形勢

  • FPNV定位矩陣
  • 市場佔有率分析：主要企業
  • 主要企業競爭情境分析

第13章競爭產品組合

  • 主要公司簡介
    • Abbott Laboratories
    • AstraZeneca PLC
    • Bayer AG
    • Becton, Dickinson and Company
    • Boston Scientific Corporation
    • Bristol-Myers Squibb Company
    • Celgene Corporation
    • Context Therapeutics Inc.
    • CooperSurgical Inc.
    • Eisai Co., Ltd.
    • Elekta AB
    • F. Hoffmann-La Roche AG
    • General Electric Company
    • GlaxoSmithKline PLC
    • Hologic Inc.
    • Johnson & Johnson Services, Inc.
    • Karyopharm Therapeutics Inc.
    • Koninklijke Philips NV
    • LiNA Medical ApS
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Siemens Healthineers AG
    • Takeda Pharmaceutical Company Limited
  • 主要產品系列

第14章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-521BAA36EC52

[199 Pages Report] The Endometrial Cancer Treatment Market size was estimated at USD 8.42 billion in 2023 and expected to reach USD 8.87 billion in 2024, at a CAGR 5.47% to reach USD 12.23 billion by 2030.

Global Endometrial Cancer Treatment Market

KEY MARKET STATISTICS
Base Year [2023] USD 8.42 billion
Estimated Year [2024] USD 8.87 billion
Forecast Year [2030] USD 12.23 billion
CAGR (%) 5.47%
Endometrial Cancer Treatment Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Endometrial Cancer Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Endometrial Cancer Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Endometrial Cancer Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AstraZeneca PLC, Bayer AG, Becton, Dickinson and Company, Boston Scientific Corporation, Bristol-Myers Squibb Company, Celgene Corporation, Context Therapeutics Inc., CooperSurgical Inc., Eisai Co., Ltd., Elekta AB, F. Hoffmann-La Roche AG, General Electric Company, GlaxoSmithKline PLC, Hologic Inc., Johnson & Johnson Services, Inc., Karyopharm Therapeutics Inc., Koninklijke Philips N.V., LiNA Medical ApS, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Siemens Healthineers AG, and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Endometrial Cancer Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Treatment
    • Chemotherapy
    • Immunotherapy
    • Radiation Therapy
  • Grade
    • Type I
    • Type II
  • End-User
    • Ambulatory Surgical Centers
    • Cancer Centers
    • Hospitals & Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Endometrial Cancer Treatment Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Endometrial Cancer Treatment Market?

3. What are the technology trends and regulatory frameworks in the Endometrial Cancer Treatment Market?

4. What is the market share of the leading vendors in the Endometrial Cancer Treatment Market?

5. Which modes and strategic moves are suitable for entering the Endometrial Cancer Treatment Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Endometrial Cancer Treatment Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevelance of type 1 and type 2 endometrial cancer worldwide
      • 5.1.1.2. Government initiatives to expand endometrial cancer treatment adoption
      • 5.1.1.3. Emergence of personalized and targeted uterine cancer therapy
    • 5.1.2. Restraints
      • 5.1.2.1. Limited reimbursement structure for endometrial treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research activities to develop novel endometrial cancer treatments
      • 5.1.3.2. Favorable government approvals for endometrial cancer drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Regulatory hurdles and risk associated with certain treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Endometrial Cancer Treatment Market, by Treatment

  • 6.1. Introduction
  • 6.2. Chemotherapy
  • 6.3. Immunotherapy
  • 6.4. Radiation Therapy

7. Endometrial Cancer Treatment Market, by Grade

  • 7.1. Introduction
  • 7.2. Type I
  • 7.3. Type II

8. Endometrial Cancer Treatment Market, by End-User

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Cancer Centers
  • 8.4. Hospitals & Clinics

9. Americas Endometrial Cancer Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Endometrial Cancer Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Endometrial Cancer Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. Abbott Laboratories
    • 13.1.2. AstraZeneca PLC
    • 13.1.3. Bayer AG
    • 13.1.4. Becton, Dickinson and Company
    • 13.1.5. Boston Scientific Corporation
    • 13.1.6. Bristol-Myers Squibb Company
    • 13.1.7. Celgene Corporation
    • 13.1.8. Context Therapeutics Inc.
    • 13.1.9. CooperSurgical Inc.
    • 13.1.10. Eisai Co., Ltd.
    • 13.1.11. Elekta AB
    • 13.1.12. F. Hoffmann-La Roche AG
    • 13.1.13. General Electric Company
    • 13.1.14. GlaxoSmithKline PLC
    • 13.1.15. Hologic Inc.
    • 13.1.16. Johnson & Johnson Services, Inc.
    • 13.1.17. Karyopharm Therapeutics Inc.
    • 13.1.18. Koninklijke Philips N.V.
    • 13.1.19. LiNA Medical ApS
    • 13.1.20. Merck & Co., Inc.
    • 13.1.21. Novartis AG
    • 13.1.22. Pfizer Inc.
    • 13.1.23. Sanofi S.A.
    • 13.1.24. Siemens Healthineers AG
    • 13.1.25. Takeda Pharmaceutical Company Limited
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. ENDOMETRIAL CANCER TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. ENDOMETRIAL CANCER TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. ENDOMETRIAL CANCER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ENDOMETRIAL CANCER TREATMENT MARKET DYNAMICS
  • FIGURE 7. ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 8. ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2023 VS 2030 (%)
  • FIGURE 10. ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 12. ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ENDOMETRIAL CANCER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. ENDOMETRIAL CANCER TREATMENT MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. ENDOMETRIAL CANCER TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. ENDOMETRIAL CANCER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 6. ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 10. ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TYPE I, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TYPE II, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 13. ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CANCER CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. CANADA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. MEXICO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 36. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 40. AUSTRALIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. INDIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. INDONESIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. JAPAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. MALAYSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. PHILIPPINES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. SINGAPORE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. SOUTH KOREA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. TAIWAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. THAILAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. VIETNAM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 80. DENMARK ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. EGYPT ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. FINLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. FRANCE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. GERMANY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. ISRAEL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. ITALY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. NETHERLANDS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. NIGERIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. NORWAY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. POLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. QATAR ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. RUSSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. SAUDI ARABIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. SPAIN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. SWEDEN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. SWITZERLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. TURKEY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. UNITED ARAB EMIRATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED KINGDOM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. ENDOMETRIAL CANCER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 144. ENDOMETRIAL CANCER TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 145. ENDOMETRIAL CANCER TREATMENT MARKET LICENSE & PRICING